Results 11 to 20 of about 111,189 (247)

Rituximab (Rituxan) [PDF]

American Journal of Neuroradiology, 2010
Rituximab is a monoclonal antibody that was first approved by the FDA as an antineoplastic agent designed to treat B-cell malignancies. This article will review the mechanism of action and clinical role of this anti-B-cell agent.
David T, Selewski, G V, Shah, R J, Mody, P A, Rajdev, S K, Mukherji   +4 more
openaire   +2 more sources

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study

Haematologica, 2018
MABLE investigated the efficacy and safety of rituximab plus bendamustine or rituximab plus chlorambucil in fludarabine-ineligible patients with chronic lymphocytic leukemia.
Anne-Sophie Michallet, Melih Aktan, Wolfgang Hiddemann, Osman Ilhan, Peter Johansson, Kamel Laribi, Balkis Meddeb, Carol Moreno, João Raposo, Anna Schuh, Ali Ünal, Tom Widenius, Alf Bernhardt, Kerstin Kellershohn, Dimitri Messeri, Stuart Osborne, Véronique Leblond   +16 more
doaj   +1 more source

Rituximab

Indian Pediatrics, 2011
Rituximab is a chimeric mouse-human monoclonal antibody against the CD 20 antigen on the surface of B lymphocytes. It binds to CD20 and causes B cell death by antibody dependant cell-mediated cytotoxicity, complement mediated cytotoxicity and apoptosis. It leads to rapid and sustained depletion of B cells.
Anupama, Borker, Narendra, Choudhary
openaire   +2 more sources

Electroretinographic improvement after rituximab therapy in a patient with autoimmune retinopathy

American Journal of Ophthalmology Case Reports, 2016
Purpose: To describe the effect of rituximab on full-field electroretinography (ERG) in a patient with nonparaneoplastic autoimmune retinopathy (npAIR). Observations: A 58-year-old male patient with visual complaints, positive anti-retinal antibodies and
Gunay Uludag, Sumru Onal, Serra Arf, Isil Sayman Muslubas, Fatih Selcukbiricik, Aylin Koc Akbay, Nil Molinas Mandel   +6 more
doaj   +1 more source

Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma

Journal of Hematology & Oncology, 2022
Inevitable relapses remain as the major therapeutic challenge in patients with mantle cell lymphoma (MCL) despite FDA approval of multiple targeted therapies and immunotherapies.
Vivian Changying Jiang, Yang Liu, Alexa Jordan, Angela Leeming, Joseph McIntosh, Shengjian Huang, Rongjia Zhang, Qingsong Cai, Zhihong Chen, Yijing Li, Yuxuan Che, Lei Nie, Ingrid Karlsson, Linda Mårtensson, Mathilda Kovacek, Ingrid Teige, Björn Frendéus, Michael Wang   +17 more
doaj   +1 more source

Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia

Haematologica, 2013
Rituximab is an effective treatment for autoimmune cytopenias associated with chronic lymphocytic leukemia. Despite the incorporation of rituximab into fludarabine-based chemotherapy regimens, the incidence of autoimmune cytopenias has remained high ...
Clifton C. Mo, Ndegwa Njuguna, Paul V. Beum, Margaret A. Lindorfer, Berengere Vire, Elinor Lee, Gerald Marti, Wyndham H Wilson, Ronald P. Taylor, Adrian Wiestner   +9 more
doaj   +1 more source

Rituximab in dermatology

Actas Dermo-Sifiliográficas (English Edition), 2013
Rituximab was introduced into clinical practice as a medication with considerable potential. Its use in patients with B-cell lymphoma and rheumatoid arthritis revealed numerous indications in autoimmune diseases, many of which involve the skin, thus requiring dermatologists to become familiar with both the characteristics of anti-CD20 antibodies and ...
A, España, E, Ornilla, C, Panizo
openaire   +2 more sources

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

Journal of Hematology & Oncology, 2012
Background The randomized phase 3 LYM3001 trial in relapsed follicular lymphoma (FL) demonstrated higher overall (ORR) and complete response (CR) rates and prolonged progression-free survival (PFS) with bortezomib-rituximab versus rituximab.
Zinzani Pier, Khuageva Nuriet K, Wang Huaqing, Garicochea Bernardo, Walewski Jan, Van Hoof Achiel, Soubeyran Pierre, Caballero Dolores, Buckstein Rena, Esseltine Dixie-Lee, Theocharous Panteli, Enny Christopher, Zhu Eugene, Elsayed Yusri A, Coiffier Bertrand   +14 more
doaj   +1 more source

Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept study

BMC Rheumatology, 2022
Background This pilot study’s primary aim was to determine if oligoclonal B cell expansion in children with Juvenile Dermatomyositis (JDM) predicts response to Rituximab therapy.
Elisa Ochfeld, Victoria Hans, Wil Marin, Najah Ahsan, Gabrielle Morgan, Lauren M. Pachman, Amer Khojah   +6 more
doaj   +1 more source

Update on rituximab [PDF]

Annals of the Rheumatic Diseases, 2005
Rituximab is a chimeric monoclonal antibody that was developed for the treatment of B cell lymphomas.1 It is directed against the CD20 cell surface molecule.2 CD20 is a tetraspan membrane protein that is present only on B cells, and is expressed initially at the immature B cell stage, remaining until the final differentiation into plasma cells.
openaire   +2 more sources